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Background: The HIV-1 envelope glycoprotein (Env) undergoes conformational changes that mediate fusion
between virus and host cell membranes. These changes involve transient exposure of two heptad-repeat domains
(HR1 and HR2) in the gp41 subunit and their subsequent self-assembly into a six-helix bundle (6HB) that drives
fusion. Env residues and features that influence conformational changes and the rate of virus entry, however, are
poorly understood. Peptides corresponding to HR1 and HR2 (N and C peptides, respectively) interrupt formation of
the 6HB by binding to the heptad repeats of a fusion-intermediate conformation of Env, making the peptides
valuable probes for studying Env conformational changes.
Results: Using a panel of Envs that are resistant to N-peptide fusion inhibitors, we investigated relationships
between virus entry kinetics, 6HB stability, and resistance to peptide fusion inhibitors to elucidate how HR1 and
HR2 mutations affect Env conformational changes and virus entry. We found that gp41 resistance mutations
increased 6HB stability without increasing entry kinetics. Similarly, we show that increased 6HB thermodynamic
stability does not correlate with increased entry kinetics. Thus, N-peptide fusion inhibitors do not necessarily select for
Envs with faster entry kinetics, nor does faster entry kinetics predict decreased potency of peptide fusion inhibitors.
Conclusions: These findings provide new insights into the relationship between 6HB stability and viral entry kinetics
and mechanisms of resistance to inhibitors targeting fusion-intermediate conformations of Env. These studies further
highlight how residues in HR1 and HR2 can influence virus entry by altering stability of the 6HB and possibly other
conformations of Env that affect rate-limiting steps in HIV entry.
Keywords: gp41, Fusion, Entry kinetics, Peptide fusion inhibitor, HIV entry, ResistanceBackground
The HIV-1 envelope protein (Env) mediates virus entry
into cells in a multi-step process, presenting many oppor-
tunities for blocking HIV infection [1-3]. The gp120 surface
subunit of Env initiates the fusion process by interacting
with CD4 and chemokine receptors. Subsequent conform-
ational changes allow the transmembrane subunit (gp41) of
Env to insert its hydrophobic N-terminus into the target
membrane, forming the pre-hairpin intermediate. Self-
assembly of the gp41 heptad-repeat regions (HR1 and
HR2) then form a thermostable six-helix bundle (6HB).
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unless otherwise stated.and virus membranes and stabilizes a fusion pore that en-
larges to allow the viral capsid to pass into the target cell
cytoplasm [2]. Neutralizing antibodies and fusion inhibi-
tors can interfere with this process, but HIV rapidly mu-
tates and evolves over the course of infection and during
treatment to evade these inhibitors [4,5]. The capacity of
HIV to mutate hinders efforts to develop broadly effective
vaccines and entry inhibitors. Furthermore, escape muta-
tions may alter the functional attributes of Env.
The first entry inhibitor licensed for clinical use,
Enfuvirtide (also referred to as T20), is a peptide that
mimics the HR2 segment of gp41 (C peptide) [6]. T20 and
other similar C peptides bind to the HR1 region of the
pre-hairpin intermediate, interrupting 6HB formation in a
dominant-negative manner to inhibit fusion [7-16]. How-
ever, T20 has a low genetic barrier to resistance, andLtd. This is an Open Access article distributed under the terms of the Creative
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[6,17-23]. While more potent, new generation C peptides
are being developed, they are still susceptible to resistance
in vitro [24-33]. The common mechanism for escape from
C peptides involves mutations within HR1 that destabilize
binding of the C peptide to a hydrophobic groove of the
HR1 trimeric, coiled-coil core of the 6HB [23,34-39]. Al-
though these mutations necessarily diminish the stability
of the 6HB, additional mutations in HR2 can compensate
for the fitness cost, and in some cases, can enhance resist-
ance [23,40-43].
Peptides that mimic HR1 (N peptides) are also potent
inhibitors, but they are generally less soluble and not yet
in clinical use. Their inhibitory mechanism remains un-
clear, but current models suggest that N peptides can
interfere with HR1 coiled-coil formation, and, especially
if stabilized as a trimer, can sequester the HR2 region of
the pre-hairpin intermediate [44-46]. In either case, as
with C peptides, formation of the 6HB is interrupted.
HIV can also develop resistance to N peptides, but un-
like C peptides, the resistance mutations stabilize the
6HB [46-49]. This finding presents a conundrum be-
cause some resistance mutations that increase 6HB sta-
bility might also increase peptide inhibitor affinity for
gp41 and therefore enhance peptide potency.
However, N-peptide resistance mutations that increase
6HB stability might also increase the rate of 6HB forma-
tion relative to peptide inhibition. Indeed, Envs with faster
entry kinetics have been reported to be less sensitive to
peptide fusion inhibitors [50-52]. Many have attributed
this finding to a shorter window of opportunity for peptide
accessibility to the pre-hairpin intermediate [50-52]. How-
ever, C-peptide fusion inhibitors have thus far not been re-
ported to select for Envs that have faster entry kinetics.
Rather, some T20-resistant Envs tended to have overall
slower entry kinetics, and only after additional compensa-
tory mutations did entry kinetics reach wild-type levels
[40,53]. Irrespective of the resistance mechanism of C-
peptides, N peptides select for different resistance muta-
tions, and their effect on Env function is unclear.
In this study, we investigated relationships between virus
entry kinetics, 6HB stability, and resistance to peptide fu-
sion inhibitors to gain insights into how residues in HR1
and HR2 can affect Env conformational changes and virus
entry. Among the sixteen independent resistant cultures
previously selected with one of three different N-peptide
inhibitors, two resistance pathways emerged that were
defined by having either a glutamic acid to lysine substi-
tution at residue 560 (E560K, HXB2 numbering) in HR1
or a glutamic acid to lysine substitution at residue 648
(E648K, HXB2 numbering) in HR2 [46,48]. Using pseudo-
virus infectivity and entry assays, we now report that in-
creased 6HB stability, but not faster entry kinetics,
correlates with resistance. We also show that increasing6HB stability is not sufficient to increase the rate of entry.
Thus, N-peptide fusion inhibitors do not necessarily select
for Envs with faster entry kinetics, nor does faster entry
kinetics predict decreased potency of peptide fusion inhib-
itors. These studies highlight an important role for HR1
and HR2 residues in influencing the relationship between
stability of the final fusion-active conformation and other
conformations of Env that regulates the rate of virus entry
into cells.
Results
Effect of different combinations of resistance mutations
on Env function
We previously generated escape-mutant viruses selected
with peptides corresponding to either 44 (N44) or 36 resi-
dues (N36 or the trimer-stabilized IZN36 [54]) in gp41
HR1 and identified two genetic resistance pathways, each
defined by a key mutation in either HR1 (E560K) or HR2
(E648K) [46,48]. Each pathway was frequently associated
with additional mutations in either the CD4 binding site
(E560K pathway) or the V3 loop of gp120 (E648K path-
way). To determine whether there were functional rela-
tionships between these gp120 and gp41 mutations, we
made several chimeric Envs and Envs with site-directed
mutations (Table 1). In one set of chimeras, we paired
gp41 resistance mutations from one pathway with gp120
mutations from the other pathway. In addition, we made
dual-pathway Envs containing the most common HR1
mutations (E560K and Q577R) and the HR2 mutation
E648K (WT-KKR, C2-KKR, and C4-KKR) because these
pathway-defining mutations were never isolated together
despite their high frequency of selection. Finally, we also
made single-site mutations that either added or removed
C-terminal cytoplasmic tail (C-tail) mutations seen in cul-
tures 4 and 5 to see whether those mutations contribute
to the functional properties of Env.
We first assessed Env function in the pseudotype infect-
ivity assay. Notably, all chimeric Envs (C4-C1, C3-C2, C2-
C3, C1-C4), including those Envs with gp41 mutations
from both (dual) pathways (WT-KKR, C2-KKR, and C4-
KKR), were highly functional and exhibited only modest
differences compared with their respective parental (se-
lected) Envs (Figure 1A; Table 2). Reversion of the C-tail
mutations (C4-C4-T and C5-C5-T) and the C-tail muta-
tions only (WT-V833I and WT-P714L) also had little ef-
fect on infectivity levels. Overall, Envs containing E560K,
including both the chimeric Envs (C4-C1, C3-C2) and the
selected Envs derived from resistance cultures C1 and C2
(C1-C1, C2-C2, C6-C6), generally conferred lower infect-
ivity than WT Env. In four of five pseudotypes with Envs
containing E648K, including the chimeric Envs (C2-C3
and C1-C4) and selected Envs derived from the resistance
cultures C3 and C4 (C3-C3 and C4-C4), infectivity was
more similar to WT. The exception was the pseudotype
Table 1 Resistance mutations in Env constructs




C1-C1 L125F, I165K N554K, E560K, V580L T641I
C2-C2 L125F, E429K E560K, Q577R
C6-C6 V169G E560K, Q577R T641I
E648K
C3-C3 T319I E648K
C4-C4 T319I, E322D, S306G Q577R T641I, E648K D620N, V833I
C5-C5 A221V, I309M, D167N E648K P714L
Chimeric
E560K
WT-C1 N554K, E560K, V580L T641I
C4-C1 T319I, E322D, S306G N554K, E560K, V580L T641I
WT-C2 E560K, Q577R
C3-C2 T319I E560K, Q577R




C2-C3 L125F, E429K E648K
WT-C4 Q577R T641I, E648K D620N, V833I
C1-C4 L125F, I165K Q577R T641I, E648K D620N, V833I
Dual KKR E560K, Q577R E648K
C2-KKR L125F, E429K E560K, Q577R E648K
C4-KKR T319I, E322D, S306G E560K, Q577R E648K
C-Tail mutations C4-C4-T T319I, E322D, S306G Q577R T641I, E648K D620N
WT-V833I V833I
C5-C5-T A221V, I309M, D167N E648K P714L
WT-P714L P714L
WT gp41 constructs C1-WT L125F, I165K
C2-WT L125F, E429K
C3-WT T319I
C4-WT T319I, E322D, S306G
aConstruct named by donor gp120-donor gp41. For example, C1-C4 represents the gp120 from culture C1 and the gp41 from culture C4.
bMutations outside of 6HB region.
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infectivity.
We next tested the chimeric Envs for susceptibility to
inhibition by the N44 N-peptide and extended the analysis
to include chimeras containing wild-type gp120 or gp41
sequences (Figure 1B-D). Most chimeras displayed resist-
ance levels similar to their respective parental Envs, in-
cluding the Envs with dual mutations from both pathways.
These findings confirm and extend our prior work show-
ing that the gp41 mutations were responsible for resist-
ance. In two cases (C3-C2 compared to C2-C2 and C1-C4
compared to C4-C4 and WT-C4), however, there were
modest differences in resistance between the chimera and
parental Envs, suggesting that cross-talk between gp120
and gp41 may modulate resistance levels (Figure 1B-C;
Table 2).Relationship between gp41 6HB stability and resistance
Using this extended panel of resistant Envs, we next
evaluated whether changes in 6HB stability among both
selected and chimeric Envs contributed to resistance.
We estimated the relative stability of different 6HBs by
determining their transition mid-point temperature (Tm)
in thermal denaturation studies using mixtures of N and
C peptides to model 6HB interactions. Using our previ-
ous Tm values [46,48], as well as additional data obtained
in the current study (Table 3), we found a strong correl-
ation between increased resistance and increased 6HB
stability (Figure 2A). For example, when the Tm in-
creased 20°C, resistance increased five-fold. Additionally,
using 50% inhibition concentrations and Tm data from
our previous study [46], we found an even stronger rela-
tionship between increased 6HB stability and resistance
Figure 1 Chimeric Env pseudotypes containing HR1 and HR2 mutations are functional and confer resistance to N44. (A) Relative
pseudovirus infectivity titered on U87-CD4-CCR5 cells in the absence of selection. Constructs are named by donor gp120-donor gp41. For
example, C1-C4 represents the gp120 from C1 and the gp41 from C4. Relative N44 resistance of pseudoviruses bearing Envs with (B) E560K
pathway mutations (checkered bars), (C) E648K pathway mutations (diagonally-hatched bars), or (D) Envs with gp120 mutations only (open bars),
with both pathway (dual) mutations (vertically-hatched bars), or with mutations to the C-terminal tail (horizontal-hatched bars). Results are
normalized to wild type (WT-WT) and averaged across two independent experiments using at least two different pseudovirus lots (±S.E.M). A full
description of Env constructs are presented in Table 1.
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and C). Indeed, for IZN36, Tm increases of 20°C led to a
nearly 100-fold increase in resistance to IZN36.Effect of resistance mutations on entry kinetics
We next assessed whether increased 6HB stability affected
the rate of virus entry, since entry kinetics has been linked
to susceptibility to inhibition by peptide fusion inhibitors
[50-52]. To measure entry kinetics, we recorded fusion
in real time using pseudoviruses that incorporated β-
lactamase-Vpr enzyme, which cleaves a fluorescent sub-
strate in the cytoplasm of target cells after virus entry
[55-58]. This assay showed that five of six Envs selected in
the resistance cultures conferred significantly slower (C1-
C1, C2-C2, C6-C6, C4-C4, C5-C5) entry kinetics relative
to WT (Figure 3A-B; Table 2). The Env from culture 3
(C3-C3), which had only a single gp41 and gp120 muta-
tion, was more similar to WT. Envs containing HR1
pathway mutations generally showed the slowest entry
kinetics, with an entry time to half maximal fusion (T1/2)
that was ~20-30% slower than WT. The same pattern
was seen for Envs containing only the gp41 mutations
(Figure 3B-C).The kinetics results were confirmed in a second assay in-
volving the addition of peptide to cultures at different time
points to measure the time during entry when Env is sus-
ceptible to peptide inhibition. The peptide prevents fusion
after Env binds to CD4 to expose the peptide-sensitive,
pre-hairpin, fusion-intermediate conformation of Env and
before formation of the 6HB. Therefore, the longer Env re-
mains sensitive to the peptide, the slower it forms the 6HB
and fusion pores that drive fusion. Results of these studies
showed that pseudotypes with Envs from resistant viruses
were not sensitive to inhibition by peptide for shorter pe-
riods of time (Figure 4A-B). In particular, pseudotypes with
Envs from the E560K pathway (C1-C1, C2-C2) were sensi-
tive to N44 significantly longer than pseudotypes with WT
Env (T1/2 ~ 75% longer), while the T1/2’s of N44 suscepti-
bility for pseudotypes with Envs from the 648 K pathway
(C3-C3, and C4-C4) were similar to WT. Thus, both assays
indicate that the mechanism of resistance does not require
faster entry into cells, and the two assays were strongly cor-
related with each other (Figure 4C).
Relationship between entry kinetics and resistance
Despite prior reports about associations between faster
entry kinetics and decreased sensitivity to peptide fusion
Table 2 Env properties on high CD4 cells
Resistance pathway Construct Infectivity Kinetics N44 resistance
Relative infectivitya,b SEM (+/−) T1/2 (min)c SEM (+/−) Relative N44 resistancea,b SEM (+/−)
WT WT-WT 1.00 0.28 53.13 0.61 1.04 0.14
C1-WT 1.77 0.11 61.83 0.80 1.09 0.07
C2-WT 1.69 0.08 61.39 2.10 1.20 0.13
C3-WT 1.07 0.10 59.00 1.26 1.10 0.05
C4-WT 2.21 0.11 58.91 1.17 1.23 0.03
WT-V833Id 1.28 0.44 56.48 1.80 1.04 0.08
WT-P714Ld 1.54 0.14 56.68 3.77 1.09 0.12
E560K WT-E560K 0.40 0.04 58.06 1.59 1.29 0.09
WT-C1 0.18 0.07 64.98 0.80 2.50 0.03
C1-C1 0.51 0.15 71.13 0.64 2.37 0.03
C4-C1 0.22 0.08 69.36 0.72 2.34 0.19
WT-C2 0.73 0.20 66.98 2.50 2.26 0.30
C2-C2 0.39 0.01 72.00 0.41 1.58 0.05
C3-C2 0.83 0.30 66.69 3.12 2.14 0.07
WT-C6 0.43 0.06 67.36 1.90 3.40 0.11
C6-C6 0.38 0.00 65.54 2.19 3.22 0.11
Dual C2-KKR 0.53 0.16 68.54 2.28 1.61 0.23
C4-KKR 0.29 0.04 67.66 0.85 1.87 0.28
WT-KKR 0.60 0.26 64.92 1.50 2.10 0.03
E648K WT-C3 1.40 0.14 48.82 0.60 1.88 0.02
C3-C3 1.23 0.36 54.41 1.85 1.84 0.21
C2-C3 1.75 0.05 64.62 3.90 1.50 0.03
WT-C4 2.35 0.65 52.92 1.35 3.59 0.16
C4-C4 1.27 0.29 58.06 1.34 3.86 0.30
C1-C4 0.81 0.20 65.18 1.76 2.52 0.04
C4-C4-Te 1.23 0.39 61.33 1.91 3.39 0.42
C5-C5 0.15 0.05 69.73 4.70 0.96 0.06
C5-C5-Te 0.26 0.06 70.28 2.30 0.90 0nnn12
aPerformed on U87-CD4-CCR5 cells.
bNormalization was performed against a different WT pseudovirus lot for each independent experiment.
cPerformed on JC53 cells.
dMutation in C-terminal tail.
eT indicates that the C-terminal tail mutation was removed.
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correlated with resistance to the N44 peptide (Figure 5A).
Rather, pseudotyped Envs that fused the slowest were still
two to three-fold more resistant than WT Envs (Figure 1B
and C). 6HB stability and entry kinetics were also not cor-
related (Figure 5B). This finding was initially surprising be-
cause 6HB formation is a major driving force in the fusion
process. Nevertheless, this result is consistent with our data
showing that N-peptide resistance is correlated with 6HB
stability (Figure 2) but not entry kinetics (Figure 5A).
Clearly, other Env interactions are more important for con-
trolling the rate-limiting step for entry than the energy con-
tributed by 6HB formation. Mutations that increase bundlestability and confer resistance to N peptides do not neces-
sarily confer inherently faster entry kinetics.
Discussion
In this study we analyzed relationships between N-peptide
resistance, 6HB stability, and entry kinetics to gain insights
into how HR1 and HR2 residues affect conformational
changes and provide new information on the Env entry
and peptide resistance mechanisms. Among our large
panel of resistant Envs, we found a correlation between in-
creased 6HB stability and increased resistance, but not be-
tween N44 resistance and entry kinetics or time to escape
from N44 inhibition. Furthermore, while providing the
Figure 2 6HB thermostablity increases with N-peptide resistance.
Scatter plots show correlation between transition mid-point
temperature (Tm) and peptide resistance of pseudoviruses relative to
wild type (WT) for (A) N44, (B) N36, and (C) IZN36. Each dot in (A)
represents the mean resistance for each Env depicted in Figure 1B and
C. Results in (B-C) were derived from Envs reported previously. Linear
regressions and statistics for correlation are indicated for each panel.
rs, Spearman correlation coefficient.
Table 3 Thermal denaturation of N and C peptide
mixtures modeling the 6HB











aall but C1-C1 and WT-KKR were determined previously.
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ity of the 6HB was not sufficient to increase the rate of
entry kinetics.
Our current study with a large panel of Envs extends
our previous work to establish the link between bundle
stability and peptide resistance. Previously, we and others
have showed that N-peptide resistance mutations that
stabilize the 6HB can confer cross-resistance to C peptides
(T20 and C34), indicating that N-peptide resistance muta-
tions provide a more universal mechanism of resistance to
fusion inhibitors compared to the C-peptide resistance
mutations [46,48,49]. Escape mutations that develop after
C-peptide selection generally destabilize interactions be-
tween Env and C peptides. Perhaps such a direct mechan-
ism of escape is not selected by N peptides because
mutations that would disrupt N peptide binding to Env
could disrupt both the conserved inner core of HR1 heli-
ces, as well as interactions between HR2 and HR1 in the
endogenous 6HB needed for virus entry. N peptides have
the potential to bind both HR1 and HR2 in the fusion
intermediate, so more than one mutation may be needed
to directly disrupt N peptide binding to Env [59]. There-
fore, the more universal mechanism of improving the
stability of the endogenous 6HB bundle to favor the virus
might be a more efficient resistance mechanism, especially
for an inhibitor that can bind to two different sites of Env.
By contrast, C peptides may not select for such an es-
cape mechanism because resistance mutations in the ex-
posed surface of the HR1 coiled coil that confer high-level
resistance to C peptides may not be overly detrimental
to 6HB formation. Nonetheless, secondary C-peptide re-
sistance mutations in HR2 do increase 6HB stability and
may directly contribute to resistance, but these mutations
generally occur after the primary resistance mutations
[23,40-43]. Indeed, a more potent C peptide inhibitor with
increased affinity for the 6HB selects a more complex pro-
file of resistance mutations, suggesting that resistancemutations that are needed to directly compete for the
higher affinity binding of the inhibitor may impose a fit-
ness cost on Env function [26]. These examples highlight
Figure 4 Resistant Envs do not lose susceptibility to inhibition
by N44 faster than WT. (A) Percent infectivity of pseudovirus on
U87-CD4-CCR5 cells after addition of N44 at different time points.
(B) Calculated T1/2 of N44 susceptibility from time of addition
experiments in (A). (C) Scatter plot correlating the T1/2 of N44
susceptibility and the T1/2 of fusion (Figure 3). *unpaired t-test
indicates P values <0.05 showing longer time of susceptibility
compared to WT. Linear regression and statistics for correlation is
indicated. rs, Spearman correlation coefficient.
Figure 3 Pseudoviruses with Envs from resistance cultures have
slower entry kinetics than WT. (A) Entry of β-Lactamase-Vpr
pseudoviruses inoculated onto HeLa cells with high CD4 and high
CCR5 receptor levels (JC53), normalized to the fusion plateau. Each
time point is the average of at least three separate pseudovirus lots
tested in independent experiments (±S.E.M). (B-C) The time to half
maximal (T1/2) fusion in target cells comparing (B) parental resistant
Envs to WT, or (C) Env containing only gp41mutations to WT.
*unpaired t-test indicates P values < 0.05.
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confer resistance and mutations that affect the inherent
kinetics and efficiency of Env entry. The interplay betweenthese attributes determines the overall fitness of the resist-
ant virus.
Notably, increasing 6HB stability confers resistance
without increasing the rate of virus entry. This finding
was initially unexpected because Envs that confer faster
Figure 5 Pseudovirus entry kinetics does not correlate with
resistance or thermodynamic stability of the 6HB. (A) Scatter
plots of the T1/2 of fusion and resistance for each pseudovirus
described in Table 1. (B) Scatter plots of the T1/2 fusion value and Tm
of each Env.
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fusion inhibitors than Envs that confer slower entry
[50-52]. In addition, increased stability of the 6HB
should facilitate formation of the final fusion-active con-
formation of Env. Two considerations may help to ad-
dress the issue of why increasing 6HB stability doesn’t
increase entry kinetics. First, high 6HB stability may in-
crease the likelihood of premature 6HB formation and
inactivation of Env, resulting in fewer functional Env tri-
mers. This could slow entry kinetics if several functional
Env trimers need to coalesce to form a fusion pore. Sec-
ond, most kinetic experiments, including our own, re-
port overall entry kinetics rather than the half-life of
discreet, peptide-sensitive fusion intermediates. In fact,
the rate constant for early steps in the fusion process,
and the relative competition between peptide association
rates and intermediate lifetimes, are both important for
defining peptide sensitivity [60,61]. It therefore remains
possible that the 6HB-stabilizing mutations shorten the
lifetime of peptide-sensitive conformational intermedi-
ates without speeding up the overall fusion process.Our experiments measuring time of escape from N44
inhibition also indicate that resistant Envs do not lose sus-
ceptibility to N44 inhibition faster than WT Env. Two al-
ternate explanations might account for this observation.
In one case, the peptide-sensitive, pre-hairpin intermediate
might indeed have a longer lifetime, but resistance can be
explained by an equilibrium between the peptide-sensitive,
pre-hairpin intermediate and a later, pre-bundle conform-
ation that is insensitive to peptide. Increased bundle stabil-
ity would favor the later peptide-insensitive conformation
and thus fusion in the presence of peptide. Alternatively,
increasing bundle stability could increase the rate of 6HB
formation and shorten the lifetime of the sensitive inter-
mediate, but the bundle-stabilizing mutations could add-
itionally affect a different conformation of Env, resulting
in slower entry kinetics. For example, the resistance muta-
tions might also impair receptor interactions or subse-
quent conformational changes and delay the start of the
window of susceptibility to peptide, without changing the
length of time of the window of susceptibility. The recent
pre-fusion structure of trimeric Env supports such a possi-
bility because gp41, and especially HR1, makes intimate
contact with the inner domain of gp120 [62-65]. The time
of escape from peptide inhibition experiments therefore
could reflect the rate-limiting steps prior to peptide inhib-
ition and make the window of peptide susceptibility look
longer in that it ends later, even if the length of the win-
dow is actually unchanged or shorter.
Conclusions
In summary, we show that mutations in HR1 and HR2
that confer resistance to peptide fusion inhibitors in-
crease 6HB stability without conferring increased entry
kinetics. Our data indicate that increased 6HB stability
does not necessarily enhance entry kinetics and that N
peptide inhibitors do not select for Envs with faster
entry kinetics. These studies highlight an important role
for HR1 and HR2 residues in influencing the relation-
ship between stability of the final fusion-active conform-
ation and other conformations of Env that regulates the
rate of virus entry into cells.
Methods
Cells
293 T cells and U87 cells expressing high levels of CD4
and CCR5 (U87-CD4-CCR5) were provided by Dan
Littman (New York University, New York, NY). HeLa
cells expressing high levels of CD4 and CCR5 (JC53)
were provided by David Kabat (Oregon Health and Science
University, Portland, OR). 293 T and HeLa cells were
passaged in Dulbecco’s modified Eagle’s medium (DMEM;
Mediatech, Inc, Manassas, VA) supplemented with 10%
fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA), 1× penicillin, 1× streptomycin, 2 mM glutamine,
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(DMEM+). U87-CD4-CCR5 cells were passaged in DMEM+
supplemented with 300 μg/ml G418 Sulfate (Mediatech,
Inc, Manassas, VA) and 1 μg/ml puromycin (Sigma, St.
Louis, MO).
Plasmids/constructs
Env-deficient HIV-1 genome (gag/pol) plasmid pCMVΔR8.2,
luciferase (Luc) reporter plasmid pHR’CMV-Luc, and
expression vector pCMV/R were obtained from Gary J.
Nabel (NIH, Bethesda, MD) and described previously [48].
pMM310-β-lactamase-Vpr reporter plasmid was obtained
from Gregory B. Melikyan (Emory Children's Center,
Atlanta, GA). JR-CSF wild-type (WT) and resistant Envs
were cloned into the pCMV/R vector as previously de-
scribed [46,48]. Chimeras between the gp120 and gp41 of
select Envs were constructed by swapping segments using
Mfe1 and Not1 restriction sites within the construct. C-
terminal tail mutations were incorporated using standard
site-direct mutagenesis techniques. The entire env gene
was sequenced to confirm that the desired mutations were
made.
Pseudovirus production
293 T cells were seeded at 3.25 × 105cells/mL in a 10-cm
dish approximately 20 h prior to transfection. Pseudovirus
stocks were obtained by transfecting cells with 0.5 μg
pCMV/R-Env, and either 4 μg each of pCMVΔR8.2 and
pHR’CMV-Luc, or 10 μg of pCMVΔR8.2 and 5 μg of
pMM310-b-lactamase-Vpr, together with Fugene 6 accord-
ing to the manufacturer’s recommendations (Promega,
Madison, WI). Media was changed at 18–20 h and at 48 h
post-transfection, supernatants were harvested and filtered
through a 0.45-μm pore-size low protein binding filter.
Virus stocks were quantified by HIV-1 p24 Gag ELISA
(AIDS Vaccine Program, NCI-Frederick Cancer Re-
search and Development Center, Frederick, MD) and
stored at −80°C.
Infectivity assay
U87-CD4-CCR5 cells were plated at 2 × 104 cells per well
in white-walled, 96-well plates (Nunclon Delta Surface,
Thermo Scientific, Denmark) and spun at 200 × g in a
Sorvall RT 6000D centrifuge (Dupont, Wilmington, DE)
for 3 min at 25°C the day prior to infection. Seven steps
of two-fold serial dilutions of pseudoviruses containing
8 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO) were
applied to cells for infection. After 24 h, an additional
100 μl of warm DMEM+ was added to each well. At ~48 h
post-infection, cells were lysed with buffer (Luciferase Cell
Culture Lysis 5x reagent, Promega, Madison, WI), and lu-
ciferase activity was assayed using kit reagents (Luciferase
Assay System, Promega, Madison, WI) according to the
manufacturer’s instructions. To determine the infectivitytiter, luciferase activity for replicate means of each dilu-
tion within the linear range were normalized by p24
Gag content and averaged across dilutions. The infectiv-
ity of at least two different pseudovirus lots was deter-
mined from separate experiments and normalized to
the average WT titer.
Peptide inhibition assay
The N44 peptide dose–response assay was performed as
described above except 300 RLU of pseudovirus was used
and peptide was added prior to adding to cells. The N44
peptide was synthesized using standard 9-fluorenylmethoxy
carbonyl chemistry and purified by high-pressure liquid
chromatography (CBER Facility for Biotechnology Re-
sources, Bethesda, MD). The sequence is based on residues
547 to 590 (HXB2 numbering), except for an isoleucine to
glycine change at position 548 (GGVQQQNNLLRAIEA
QQHLLQLTVWGIKQLQARILAVERYLKDQ). The 50%
inhibitory concentration (IC50) of N44 was determined
from dose–response curves using non-linear regression
analysis in Graph Pad Prism 6 (Graph Pad Prism Software,
San Diego, California). Experiments were performed in
duplicate and at least two different pseudovirus lots were
used in independent experiments to determine the sensi-
tivity to N44. The IC50values were normalized against WT
for each individual experiment before averaging across ex-
periments to give the mean relative resistance.
Kinetic assay
JC53 cells, frequently used for beta-lactamase kinetic as-
says, were plated at 2 × 104 per well in clear-bottom, black-
walled, 96-well plates (Costar, Corning Inc., Corning, NY)
the day prior to the assay [55-57,61]. Beta-lactamase load-
ing solution (Life Technologies, Madison, WI) was pre-
pared at room temperature using DMEM (minus phenol
red) supplemented with 25 mM HEPES, 2 μM CCF2-AM
Dye (Solution A), 10 μL per mL of Solution B, 157 μL per
mL of Solution C, and 3.1 mM probenecid (Sigma-Aldrich,
St. Louis, MO). Cells were washed with Hanks Buffered
Saline Solution (HBSS; Mediatech, Inc, Manassas, VA),
prior to adding 50 μl of loading substrate to each well.
Cells were allowed to take up substrate for 1 h at room
temperature in the dark prior to placing on ice. Mean-
while, β-lactamase-containing pseudoviruses were first
thawed at room temperature, then placed on ice and di-
luted into ice-cold DMEM+ supplemented with probene-
cid and polybrene for final concentrations of 2.5 mM and
8 μg per mL, respectively. After this initial 1.3-fold dilu-
tion, three additional 1.4-fold serial dilutions of each pseu-
dovirus were applied in duplicate to cells that had been
washed twice with HBSS containing 2.5 mM probenecid.
These dilutions spanned the entire dynamic range of
the assay for most pseudoviruses tested (Additional
file 1: Figure S1). All manipulations were performed on
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aluminum block covered with a wet paper towel and
immersed in ice to keep the cells cold throughout washing
and pseudovirus application. Pseudoviruses were spinocu-
lated in the Sorvall RT 6000D centrifuge for 30 min at 4°C
and 2500 × g and then immediately placed into a Spectra
Max Gemini EM (Molecular Devices, Sunnyvale, CA)
fluorescence plate reader at 37°C. Florescence changes
were monitored over time using a 409 nm excitation and
both a 460 nm (blue) and 528 nm (green) emission detec-
tion. We measured fusion for 100 minutes to capture
maximum fusion, which was comparable to time points
reported by others using similar assays [56,58]. We also
noticed that control pseudoviruses without Env produced
a time-dependent increase in background signal as in-
cubation periods approach 100 min (Additional file 1:
Figure S1).
To obtain the working fusion signal in florescence units,
the blue:green ratio for wells mock treated only with
DMEM+ was subtracted from the blue:green ratio of wells
treated with pseudovirus. The signal at each time point
was normalized to the signal at 100 min. The normalized
signal for each replicate was averaged prior to averaging
across the four dilutions to give the final entry kinetic
curve. This trace was fitted to a 4-parameter logistic equa-
tion to obtain the T1/2 (min) for each pseudovirus using
Graph Pad Prism 6. Three independent measurements of
time to half-maximal fusion (T1/2) were determined for
each Env using at least three different pseudovirus lots.Time to escape N44 inhibition
U87-CD4-CCR5 cells were plated as described above for
the infectivity assay. The following day the cells were
cooled on ice, and media was removed. 100 μl of pseudo-
virus containing 8 μg/mL of polybrene were spinoculated
in the Sorvall RT 6000D centrifuge for 30 min at 4°C and
2500 × g. Pseudovirus was then removed and 75 μl of
DMEM+ warmed to 37°C was added to start infectivity
and placed into a 37°C incubator. 25 μl of 20 μM (excess)
N44 was then added to the cells at times corresponding to
0, 5, 10, 15, 20, 25, 35, 55, 75, 100, and 150 min incuba-
tions at 37°C. Additionally, 25 μl of diluent without N44
was added at 150 min to serve as a control to normalize
for total infectivity. 24 h later, DMEM+ warmed to 37°C
was added, and the assay plate was allowed to incubate for
another 24 hr. Luciferease activity was then assayed as de-
scribed above and normalized to the infectivity of the
150 min time point without peptide. Samples were run in
duplicate, and at least two independent experiments were
performed using different pseudovirus lots. The time
course was fit to a 4-parameter logistic equation with a
constraint that the bottom asymptote must be equal
to zero to determine the T1/2 (min) using Graph PadPrism 6. All independent measures of T1/2 (min) were
then averaged.
Circular dichroism experiments
6HB stability studies were performed as previously de-
scribed [46,48]. In this study, 10 μM of each HR1 and HR2
peptide (KKR- and C1-mutant, respectively) were mixed in
sodium phosphate buffer (PBS) at room temperature. A
Jasco spectropolarimeter (model J-810, Jasco Inc., Easton,
MD) was used to collect circular dichroism (CD) spectra
of this peptide mixture. Thermal denaturation was mo-
nitored at 220 nm between 4° and 95°C. The transition
mid-point temperature (Tm) was estimated from the first-
derivative of the denaturation curves using Jasco software
utilities.
Statistical analysis
Spearman correlation coefficients were used to determine
correlations, and t-tests were performed using GraphPad
Prism software. P values < 0.05 were considered signifi-
cant. Comparisons were made using mean values from dif-
ferent pseudovirus lots for a particular Env. Unpaired,
parametric two-tailed t-tests were used as indicated in the
figure captions.
Additional file
Additional file 1: Figure S1. Raw kinetic data. (A) Representative real
time entry for four serial dilutions (1.3-fold to 3.6-fold) of the WT β-lam
pseudovirus. (B) Representative real time entry for the lowest dilutions of
either WT Env, C1-C1 Env, or the no HIV Env control β-lam pseudoviruses.
(C) Entry kinetics for WT-WT and C1-C1 using the no HIV Env as the
background control. Here the kinetic relationships are preserved using this
alternate background correction. Error bars, standard deviation of mean for
each time point. Inset, T1/2 of each of the curves in (±95% C.I).
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